| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
We clarified antiangiogenetic effect of Itraconazole, one of the antifungus drugs. This effect is based on the mechanism which is quite different from that of Bevacizumab. We also clarified it is based on direct anti-proliferation effect on endothelial cells not based on other angiogenetic cytokines. Our results showed that this Itraconazole’s effect is same as mTOR inhibitor, less toxicity than mTOR inhibitor and synergic effect with Bevacizumab on Bevacizumab resistant cancer cell.
|
